Skip to main content


Hydroxychloroquine Shortage During COVID-19

Jan 12, 2021

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.

Despite public, political and quasi research evidence supporting

Read Article

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
Broadalumab the other IL-17 inhibitor, is FDA approved for psoriasis. The AMVISION-1 & AMVISION-2 ph III trials in psoriatic arthritis showed in 962 PsA pts it was effective w/ week 16 ACR20 of ~46% (vs 21% PBO).

Dr. John Cush RheumNow ( View Tweet)

Jan 06, 2021

Best of 2020: The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

Filgotinib Bows Out of the RA Race in the USA

Dec 16, 2020

Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).

Read Article

Systemic Steroids Seldom Flare Psoriasis

Dec 09, 2020

A tenet of drug management suggests that steroid use in psoriasis may be associated with rebound flares; well this has been challenged by a new observational trial showing that the risk of flares (and severe flares) of psoriasis flares were seldom triggered by systemic steroids - certainly

Read Article

Upadacitinib Effective in Biologic Refractory Psoriatic Arthritis

Dec 08, 2020

The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.

Read Article

PIANO Study - Safety of Biologics in Pregnancy

Dec 03, 2020

The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.

Read Article
Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis!

Janet Pope Janetbirdope ( View Tweet)

Nov 07, 2020
Perform (annual) skin exams in patients in MTX based on discovery of a new adverse effect signal with use of low dose MTX (median dose 15 mg/wk) with a NNH of 167! Screening 160 RA patients on MTX will identify 1 skin Ca. Amazing #ACR20 Year in Review by @JYazdanyMD.
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Nov 06, 2020
Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Nov 05, 2020

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

Nov 03, 2020

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 

This phase 3 study, enrolled biologic-

Read Article
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

Dr. John Cush RheumNow ( View Tweet)

Nov 02, 2020

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on

Read Article

Guselkumab, an IL-23 Inhibitor, Effective in Psoriatic Arthritis

Oct 28, 2020

The DISCOVER‐2 trial has shown that guselkumab, an interleukin‐23p19 was shown to be safe and effective in biologic‐naïve psoriatic arthritis (PsA) patients in a one year study.

This was a phase III trial that enrolled  biologic‐naïve PsA patients with active disease (≥5 swollen+≥5

Read Article
Swedish population study of psoriasis pts Rx w/ secukinumab (848) or ustekinumab (1107) showed slightly more respiratory infx & UTI (HR 1.22), w/ no difference in hospital treated severe respiratory, UTI (HR 0.96) or candidiasis (HR 1.80)

Dr. John Cush RheumNow ( View Tweet)

Oct 06, 2020
Meta-analysis shows smoking increases the risk of psoriasis (OR: 1.84) in the general population, but smoking the risk of PsA among psoriasis patients (OR: 0.70) but was equal to the general populatoin.

Dr. John Cush RheumNow ( View Tweet)

Oct 01, 2020
The RheumNow Podcast is up! Cardiovascular Risk in Psoriatic Disease, Higher COVID rates in young adults, Reimbursements for Rheumatologists and more.

Dr. John Cush RheumNow ( View Tweet)

Sep 27, 2020
High-risk coronary plaques (LRNC) assessed by Coronary CT scores in 209 biologic naive Psoriasis pts. LNRC correlated w/ Framingham risk & Dz activity.

Dr. John Cush RheumNow ( View Tweet)

Sep 25, 2020

Romilkimab Effective in Early Diffuse Systemic Sclerosis

Sep 24, 2020

A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).

Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4

Read Article
The EMAs Committee for Medicinal Products for Human Use (CHMP) has recommended baricitinib for approval in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

Dr. John Cush RheumNow ( View Tweet)

Sep 23, 2020

Updated List of Drugs Inducing Lupus

Sep 14, 2020

Drugs inducing lupus may account for nearly 30% of all subacute cutaneous lupus erythematosus (CLE) and up to 15% of systemic lupus erythematosus (SLE) cases. Moreover there are over 100 drugs capable of inducing drug-induced lupus erythematosus. A population based report in JAMA

Read Article

Comorbidities Impact Disease Activity in Spondyloarthritis

Sep 13, 2020

An analysis of a large population-based cohort of axial spondyloarthritis (axSpA) patients shows that comorbidities are common and are associated with higher disease activity and higher levels of functional impairment.

Read Article
Study of 211 SSc pts (70% with limited SSc) & during 120 (50-216) mos F/U, 105 (50%) had 1 or more skin ulcer (SU); 66% recurrent/persistent SUs.

Dr. John Cush RheumNow ( View Tweet)

Sep 02, 2020
Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib

Dr. John Cush RheumNow ( View Tweet)

Aug 26, 2020